Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%,
This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Age
22 - No limit years
Sex
ALL
Healthy Volunteers
No
R and R Eye Research, LLC
San Antonio, Texas, United States
Start Date
October 28, 2025
Primary Completion Date
May 31, 2029
Completion Date
May 31, 2031
Last Updated
October 20, 2025
400
ESTIMATED participants
Bimatoprost Implant System
DRUG
SpyGlass IOL
DEVICE
Timolol Maleate Ophthalmic Solution, 0.5%
DRUG
Commercial IOL
DEVICE
Lead Sponsor
SpyGlass Pharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07396441